The objective of the study is to compare the efficacy of intranasal oxytocin versus
intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms
despite being on adequate treatment with antipsychotic medication.
Phase:
N/A
Details
Lead Sponsor:
University of California, Irvine University of California, San Diego
Collaborators:
National Institute of Mental Health (NIMH) University of California, San Diego